TOP: American Academy of Neurology 2026 Annual Meeting LEFT: PRESENTATION April 20, 2026 RIGHT: Abstract Title: A Study of NE3107 (Bezisterim) in Early Parkinson’s Disease (SUNRISE-PD): Baseline Demographics and Characteristics Authors: J. Palumbo, C. Ahlem, C.L. Reading, S. O’Quinn, J. Zhang, M. Stacy)

BioVie will present an abstract from the SUNRISE-PD study on its lead candidate bezisterim, in the treatment of Parkinson’s Disease at the upcoming #AANAM in Chicago.

Details here: investors.bioviepharma.com/news/news-de...

#ParkinsonsDisease #ScientificExchange #Neurology #NeuroSky

We stand with the millions of people living with Parkinson’s to help raise awareness, education, & hope for this progressive neurodegenerative disease that impacts movement, cognition & quality of life.
#ParkinsonsAwarenessMonth #ParkinsonsResearch #HopeForPD

Neuroinflammation and the resulting insulin resistance can disrupt how dopamine works in the 🧠. When the neurons lose efficient access to glucose and are starved of energy, these cells begin to falter, and the brain’s ability to control movement starts to break down.
#ParkinsonsDisease #Neurosky

GRAPHIC with copy on the left that reads: In Parkinson’s disease brain signals get stuck in traffic. Inflammation and insulin resistance can disrupt dopamine signaling in the brain. BioVie is advancing research to target inflammation and insulin resistance in the brain to address neurological diseases, including Parkinons’s disease. On the right is a drawing of a brain with a few cars and traffic lights to illustrate the disruption of dopamine signaling.

Dopamine is one of the most common terms associated with Parkinson’s because it helps mediate smooth, controlled muscle movements. Yet when levels in the brain are too low, motions may become slow, shaky, and halted. Why? #ParkinsonsDiseaseAwarenessMonth

Graphic with text that reads: APRIL IS Parkinson’s Disease Awareness Month Image of 5 red tulips with BioVie’s logo and a grey ribbon

During #ParkinsonsAwarenessMonth we honor people living with PD and their family, friends, nurses, & doctors who stand with them. BioVie is proud to support the Parkinson’s community and is committed to advancing innovative therapies for neurological disorders, including PD.

Image of 5 smiling people depticting doctors (from left - man wearing blue scrubs, woman in white coat, woman in white coat, man wearing blue scrubs, woman in white coat) Text reads: March 30 National Doctors Day Footer reads: bioVie (company logo)

To all the physicians conducting research, testing new therapies, treating patients, and providing support for people with #neurological & #neurodegenerative diseases & disorders, on #NationalDoctorsDay, we say THANK YOU.
#Alz #Parkinsons #longCOVID #Medsky 🩵🩺

BioVie targets Parkinson’s at its source with lead drug bezisterim For decades, treatment of Parkinson’s disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease’s hallmark motor...

#Parkinson’s affects ~1M people in the U.S. w/ prevalence expected to rise with aging population. Yet treatment has changed little in 50 years. Our lead drug candidate, bezisterim (NE3107), addresses the underlying neurodegeneration by targeting #inflammation that causes insulin resistance. Read ⬇️

BioVie's investigational drug bezisterim targets these upstream inflammatory pathways - and is currently in Phase 2 trials for Parkinson’s & LongCOVID.

The ADDRESS-LC study in adults with #LongCOVID is actively recruiting in the U.S. addresslongcovid.com #BrainWeek

Graphic of a brain BRAIN AWARENESS WEEK March 16-22, 2026

Some of the most challenging #neurological conditions of our time share a common biology with evidence pointing to #inflammation & insulin resistance as mechanisms underlying #Alzheimer’s, #Parkinson's, & #LongCOVID. #BrainAwarenessWeek

ADDRESS: Long COVID Clinical Study | BioVie Pharma ADDRESS: Long COVID- Clinical study evaluating anti-inflammatory drug for underlying the neurological symptoms of Long COVID.

Our P2 ADDRESS-LC trial evaluating bezisterim in adults experiencing #brainfog & #fatigue is recruiting at 18 U.S. sites. You may be eligible. Learn more: addresslongcovid.com #LongCOVID #ClinicalTrials

Long COVID Awareness Day March 15, 2026

On #LongCOVIDAwarenessDay, we recognize the millions of people still living with the debilitating effects - including #neurological symptoms such as brain fog and fatigue - long after their initial COVID-19 infection.

AD/PD 2026 Advances in Science & Therapy Presentation March 19, 2026 Abstract Title: Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson’s Disease (SUNRISE-PD) Authors: Joseph M. Palumbo; Clarence Ahlem; Christopher L. Reading; Stephen O’Quinn; Jeffrey Zhang; Mark Stacy

BioVie will present an abstract from the SUNRISE-PD study on its lead candidate bezisterim, in the treatment of #Parkinson’s at the upcoming #ADPD2026 annual meeting in Copenhagen.

Details here: investors.bioviepharma.com/news/news-de...

#ScientificExchange #Neurology #Neuroscience $BIVI

How Covid Quietly Rewires the Brain Researchers keep discovering more about the long-term neurological effects of SARS-CoV-2.

Many of the most common #longCOVID symptoms are neurological - #fatigue, #brainfog, cognitive slowing, and memory decline. Research indicates that lingering #inflammation & #biological changes associated with accelerated #aging may be driving these effects in some patients.

REMINDER BioVie to Host Live Investor Webinar and Q&A on Wednesday, March 4 at 4:15 p.m. ET

A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim’s effects on #inflammation and insulin resistance, two key drivers of #Alzheimer’s, #Parkinson’s, and #LongCOVID.

Register here: www.redchip.com/webinar/BIVI...

#Neuroscience $BIVI

The Innovators Podcast - Joseph Palumbo MD - Chief Medical Officer of BioVie Spotify video

Our CMO, Dr. Joseph Palumbo joined The Innovators Podcast to discuss BioVie’s mission to develop new treatments for #neurological & #neurodegenerative disorders & what it takes to bring a drug from idea to clinic.

Listen here: open.spotify.com/episode/1UZX...

#Parkinsons #LongCOVID #Alz

CORPORATE UPDATE BioVie to Host Live Investor Webinar and Q&A on Wednesday, March 4

Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on Wednesday, March 4.

Register here: investors.bioviepharma.com/news/news-de...

#Alzheimers #Parkinsons #LongCOVID #Neuroinflammation #InsulinResistance $BIVI

Image of two people holding hands with the words Thank you Caregivers

Behind every person living with a neurological disease or disorder is a network of caregivers: family, friends, professionals, & advocates who provide essential support. On #NationalCaregiversDay, and every day, we recognize the critical role they play and say THANK YOU! #Alz #Parkinsons #LongCOVID

While the higher reported symptom burden in the U.S. may reflect lower stigma and greater access to neurological and mental healthcare rather than more severe disease, #brainfog and #fatigue were among the most common neurological symptoms across all countries. #LongCOVID

BioVie could offer first new Parkinson’s therapy in decades In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc...

#Parkinson’s care has focused on dopamine for decades.
BioVie ($BIVI) is testing a different angle: targeting brain inflammation + insulin resistance.

Phase 2 SUNRISE-PD enrollment complete with topline data expected Apr/May 2026.

Multiple 2026 catalysts ahead.
#Biotech #BIVI

American College of Psychiatrists Annual Meeting Poster Presentations February 18, 2026 Abstract Title: Bezisterim-Associated Anti-inflammatory Epigenetic Modulation of Age Acceleration and Cognition in Alzheimer's Disease Authors: Joseph M. Palumbo; Christopher L. Reading; Jiayan Yan, Clarence Ahlem; Penelope Markham; Stephen O'Quinn; Varun B. Dwaraka Abstract Title: Baseline Characteristics of Currently Enrolled Participants in Phase 2 Study of Bezisterim (NE3107) in Long COVID (ADDRESS-LC) Authors: Joseph M. Palumbo; Penelope Markham; Michael Peluso; Igor J. Koralnik; Sherry Hsiang-Yi Chou; Lisa McCorkell; Chantal Petit; Stephen O'Quinn; Chris Reading; Clarence Ahlem; Jiayan Yan

BioVie announced the acceptance of two abstracts from studies on our lead candidate bezisterim, in the treatment of #Alzheimer’s & #LongCOVID at the upcoming 2026 American College of Psychiatrists (ACP) annual meeting.

Read: investors.bioviepharma.com/news/news-de...

#ScientificExchange #BIVI

📍There are 18 sites actively recruiting across the U.S.

To learn more about participating in the ADDRESS-LC trial visit addresslongcovid.com

Together, these organizations have given voice to millions suffering in silence. Our team, and #LongCOVID patients, researchers, & doctors are grateful for your active participation + determination to advance research toward a treatment. THANK YOU! 🧡
#Advocacy #PatientCentricResearch

Advancing Science with Support from Advocacy Partners THANK YOU Logo Solve M.E. Logo Patient-Led Research Collaborative

BioVie’s current P2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms associated with #LongCOVID was designed to address the unmet needs of the community and made possible with support from @solveme.bsky.social & @patientled.bsky.social.

THANK YOU #MichaelJFoxFoundation, #DavisPhinneyFoundation, & @parkinsondotorg.bsky.social!

Our team, and the Parkinson’s community at large, is grateful for your fierce dedication to advancing research toward treatments for patients.

#ParkinsonsDisease #Advocacy #PatientCentricResearch #BIVI

Advancing Science with Support from Advocacy Partners THANK YOU Logos for: The Michael J. Fox Foundation for Parkinson's Research Davis Phinney Foundation for Parkinson's Parkinson's Foundation

Enrollment in BioVie’s Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease was made possible with the support of leading advocacy organizations.

Clinical Trials & Pharma Engagement:

• Worked with @biovie.bsky.social on study design & recruitment for their Bezisterim trial for #LongCovid, an investigational drug that has shown promise in neurodegenerative conditions. /5

Our CEO, Cuong Do, spoke with @charlespiller.bsky.social about patterns of alleged misconduct at certain South Florida clinical trial sites, and the devastating implications for the Alzheimer’s community- from patients & families to researchers & drug developers seeking to make a difference.

Parkinson's Update BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease

Enrollment is complete in our Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease. Topline results expected in 1H 2026.

Learn more: investors.bioviepharma.com/news/news-de...

#Neurology #BIVI

At BioVie, we are actively studying bezisterim in Long COVID - for information about the currently enrolling ADDRESS-LC trial visit addresslongcovid.com

Read the study here www.nature.com/articles/s41...

#Neuroinflammation #InsulinResistance #LongCOVID

“Bezisterim has demonstrated the ability to modulate key inflammatory pathways implicated in the chronic inflammation seen in long COVID, that also play a key role in neurodegenerative diseases of aging, like Parkinson’s and Alzheimer’s.” -Cuong Do President & CEO, BioVie

A study published in @natimmunol.nature.com provides additional evidence that #LongCOVID is associated with chronic #inflammation & metabolic dysregulation. The findings align w/ the MoA of bezisterim, which targets upstream immune signaling involved in chronic inflammation.

#BrainFog #Fatigue